View our research and studies on Prevagen®
Madison Memory Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of Apoaequorin in Community-Dwelling, Older Adults
The primary objective of the Madison Memory Study was to examine the effect of Prevagen® on cognitive function in a study population of community dwelling, older adults with self-reported cognitive difficulties or concerns. Changes in cognitive function were quantitatively assessed using tests from the CogState Research battery.
Prevagen demonstrated the ability to improve aspects of cognitive function in older participants with either normal cognitive aging or very mild impairment, as determined by AD8 screening.
We designed this study to assess the effects of our supplement of apoaequorin on verbal learning and working memory. The current study was a randomized, double-blind, placebo-controlled trial. Participants were 218 community-dwelling adults, aged 40-91 years, with self-reported memory concerns. The results indicated a strong relationship between apoaequorin and improvements on a quantitative measure of cognitive function, specifically verbal learning.
The Prevagen Quality of Life Study was an open-label study of 56 generally healthy participants over a 90 day period measuring perceived changes in overall cognition and general health. Changes in performance were measured via a standardized battery of questions. The results of the study show improved performance across all parameters.
Dosing in the animal study was the equivalent of 4,000 times the recommended daily amount of Prevagen 10mg and 2,000 times the recommended daily amount of Prevagen Extra Strength 20mg. There was No Observed Adverse Effect Level (NOAEL) at the highest dose. Research was conducted by Eurofins/Product Safety Labs under the advisement of Soni and Associates, Inc. Funding provided by Quincy Bioscience.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Apoaequorin is not expected to have any significant risk of allergic cross-reactivity for those who are allergic to known allergens. We conducted a bioinformatics assessment of apoaequorin against known allergens and a laboratory test to asses potential allergenicity by simulating gastric digestion of apoaequorin’s amino acid sequence. These tests are considered highly predictive of allergenic potential. The results from the bioinformatics searches with the apoaequorin sequence show that it is not a known allergen and not likely to cross-react with known allergens. Research was conducted by Goodman group at Food Allergy Research and Resource Program at University of Nebraska, Lincoln, NE. Funding provided by Quincy Bioscience.
Quincy Bioscience has had a long standing sponsored research agreement with the UWM Neuroscience department and the laboratory of Dr. James R. Moyer. The UWM lab has provided critical insight into the interaction between apoaequorin and hippocampal neurons in animal models. The lab has published and presented several papers at international neuroscience conferences related to apoaequorin and its functionality.
Aging and how Prevagen® can help
In the United States, 10,000 baby boomers turn 50 every day. And although a touch of gray hair can look distinguished, there are other age-related issues that may be unwanted, such as the normal memory loss associated with aging. Your brain is made up of many small cells, and controls everything you do. Prevagen with the patented ingredient apoaequorin supports healthy brain function.*
Researchers have discovered that Apoaequorin actually supports healthy brain function*
Recently, scientists made a significant breakthrough in brain health with the discovery that apoaequorin can support healthy brain function.*